Xtacy Therapeutics Corp. Stock price

Equities

XTCY

CA98423G1072

Investment Management & Fund Operators

Market Closed - Canadian Securities Exchange 03:13:20 2024-03-28 pm EDT 5-day change 1st Jan Change
0.04 CAD 0.00% Intraday chart for Xtacy Therapeutics Corp. -11.11% -11.11%
Sales 2021 - Sales 2022 - Capitalization 7.51M 10.18M
Net income 2021 -3M -4.07M Net income 2022 -1M -1.36M EV / Sales 2021 -
Net Debt 2021 50.91K 68.99K Net Debt 2022 25.37K 34.37K EV / Sales 2022 -
P/E ratio 2021
-1.09 x
P/E ratio 2022
-3.97 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 89.2%
More Fundamentals * Assessed data
Dynamic Chart
Xtacy Therapeutics Corp. Expands MDMA Platform Pharmaceutical Grade Psychedelic Solutions to Solve Unmet Medical Needs CI
Global Wellness Strategies Inc. will Change its Name to XTACY Therapeutics Corp CI
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Global Wellness Strategies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Global Wellness Strategies Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
Global Wellness Strategies Inc. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Global Wellness Strategies Inc. Auditor Raises 'Going Concern' Doubt CI
Global Wellness Strategies Inc. Announces Formation of Wholly Owned Pharma Subsidiary Focused on Clinical Trials CI
Global Wellness Strategies Effervescent Cannabis Products Approved to Launch GWS Achieves Major Milestone Partnering with Hempsana Holdings CI
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022 CI
Global Wellness Strategies Inc. Signs Custom Manufacturing Agreement with Hempsana Holdings CI
Global Wellness Strategies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022 CI
Global Wellness Strategies Inc. Announces Shanti Therapeutics Mdma Clinical Trial Update CI
Global Wellness Strategies Inc. Announces Appointment of Sud Agarwal as the Chief Medical Advisor CI
Global Wellness Strategies Inc. Announces Their Brand KaleidoMyco to Launch Their Proprietary Fizz Tablets CI
More news
1 week-11.11%
Current month-20.00%
1 month-20.00%
6 months-60.00%
Current year-11.11%
More quotes
1 week
0.04
Extreme 0.04
0.05
1 month
0.04
Extreme 0.04
0.08
Current year
0.03
Extreme 0.03
0.10
1 year
0.02
Extreme 0.02
0.19
3 years
0.02
Extreme 0.02
0.50
5 years
0.02
Extreme 0.02
0.80
10 years
0.02
Extreme 0.02
2.80
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17-11-29
Director of Finance/CFO 70 19-04-09
Corporate Secretary - -
Members of the board TitleAgeSince
Director of Finance/CFO 70 19-04-09
Director/Board Member 67 17-05-11
Chief Executive Officer - 17-11-29
More insiders
Date Price Change Volume
24-03-28 0.04 -11.11% 10,000
24-03-25 0.045 -35.71% 30,000
24-03-22 0.07 +55.56% 3,000
24-03-21 0.045 -10.00% 20,000
24-03-20 0.05 +11.11% 10,000

Delayed Quote Canadian Securities Exchange, March 28, 2024 at 03:13 pm EDT

More quotes
XTACY Therapeutics Corp. is a Canada-based prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for consumer wellness products. The Company's investment strategy is focused on the specific areas of pain, depression and mental illness. The focus of the Company is on global wellness, psychedelics, mycology, hemp and cannabidiol (CBD), healthcare-related target companies and their clinical studies and trials. By investing in techniques, such as micro-dosing using organic compounds and synthetic molecules, the Company is focusing on the research with the aim of providing wellness benefits with less side effects for people and the planet.
More about the company
  1. Stock
  2. Equities
  3. Stock Xtacy Therapeutics Corp. - Canadian Securities Exchange